Home/Curavac/Nicolas Havelange

NH

Nicolas Havelange

Chief Operating Officer

Therapeutic Areas

Autoimmune Diseases

Curavac Pipeline

Drug	Indication	Phase
CV-MG02	Myasthenia Gravis (MG)	Phase 2

Leadership Team at Curavac

Dr. Stéphane Huberty

Founder and Chief Executive Officer

Dr. Jean-Paul Prieels, Ph.D.

Chief Scientific Officer

Matthieu André

Chief Financial Officer

Dimitri F. Dimitriou

Executive Chairman of the Board

View full Curavac profile